Skip to main content
. 2020 Sep 16;8(9):355. doi: 10.3390/biomedicines8090355

Figure 6.

Figure 6

Figure 6

Forest and funnel plots showing effect estimates of complement inhibition (clinical trials) corresponding to (a) the treatment of rgMG crises, (b) the prevention of new acute AMR episodes, and (c) the prevention of DGF after kidney transplantation. AMR, antibody-mediated prevention; CI, confidence interval; M–H, Mantel–Haenszel test; PBO, placebo; rgMG, refractory generalized myasthenia gravis; SE, standard error.